Stryker (SYK)
(Delayed Data from NYSE)
$328.45 USD
+1.82 (0.56%)
Updated May 3, 2024 04:00 PM ET
After-Market: $328.52 +0.07 (0.02%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$328.45 USD
+1.82 (0.56%)
Updated May 3, 2024 04:00 PM ET
After-Market: $328.52 +0.07 (0.02%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth A Momentum C VGM
Zacks News
Should You Sell Stryker (SYK) Stock Before Earnings?
by Zacks Equity Research
Stryker (SYK) might report a beat in the to be reported quarter on the back of its favorable Zacks Rank and positive Earnings ESP.
Medical Product Stocks Earnings on Apr 25: SYK, EW, LH
by Zacks Equity Research
Medical is one of the broader sectors among the 16 Zacks sectors that are expected to report earnings growth in the first quarter.
Will Stryker (SYK) Deliver a Beat this Earnings Season?
by Zacks Equity Research
Stryker Corporation (SYK), a leading player in the medical technology space, is set to report first-quarter 2017 results on Apr 25 after the bell.
Stryker Launches MAKO Robotic-Arm for Knee Anthroplasty
by Zacks Equity Research
Stryker Corporation (SYK) recently announced the commercial launch of a robotic-arm assisted total knee arthroplasty application based on its flagship MAKO System.
Why Is Stryker Corp (SYK) Up 5% Since the Last Earnings Report?
by Zacks Equity Research
Stryker Corp (SYK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Stryker (SYK) Beats Q4 Earnings, Provides FY17 Guidance
by Zacks Equity Research
Maintaining its streak of positive earnings surprises, Stryker Corp (SYK) reported adjusted earnings of $1.78 per share in the fourth quarter of 2016, which comfortably beat the Zacks Consensus Estimate by 2 cents.
Should You Sell Stryker (SYK) Before Earnings?
by Zacks Equity Research
Investors are always looking for stocks that are poised to beat at earnings season and Stryker Corporation (SYK) may be one such company.
Medical Product Stocks Q4 Earnings Roster: SYK, ISRG, RMD
by Zacks Equity Research
Medical is one of the broader sectors among the 16 Zacks sectors that is expected to report earnings growth in the fourth quarter.
The Zacks Analyst Blog Highlights: Intuitive Surgical, Stryker and Hologic
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Intuitive Surgical, Stryker and Hologic
Stryker (SYK): Can It Post a Beat this Earnings Season?
by Zacks Equity Research
Delving deeper into the fundamentals of Stryker Corporation (SYK), we expect the stock to beat earnings estimates this quarter.
3 Medical Device Stocks Likely to Beat Earnings Estimates
by Zacks Equity Research
The likely revocation of the 2.3% medical device excise tax is going to be a big bonus for both the behemoths and small players.
Stryker (SYK) to Pay for Rejuvenate and ABG II Modular-Neck
by Zacks Equity Research
Stryker Corporation (SYK) announced that it has reached an agreement to compensate patients for Rejuvenate and ABG II Modular-Neck surgeries done prior to Dec 19, 2016.
Top Research Reports for Amazon, Ford & Dow Chemical
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Amazon (AMZN), Dow Chemical (DOW) and Ford (F).
Fresh Research Reports For Intel (INTC), AT&T (T) & Others
by Sheraz Mian
Today's must-read reports are for Intel (INTC), Biogen (BIIB) and AT&T (T).
5 Skyrocketing Momentum Stocks
by David Bartosiak
Five red hot momentum stocks breaking out to new highs
MedTech Industry Stock Outlook - Dec. 2015
by Zacks Equity Research
While the global economy has been on a rollercoaster ride over the past quarter, the MedTech sector has not only held its own, but maintained a stable uptrend.
MedTech Industry Stock Outlook - Dec. 2015
by Zacks Equity Research
While the global economy has been on a rollercoaster ride over the past quarter, the MedTech sector has not only held its own, but maintained a stable uptrend.
Should You Buy Evolving Trends in Medical Devices?
by Zacks Equity Research
Given the U.S. government's pushback on tax-dodging, we expected some sloth to creep into the medical device space as far as M&As are concerned. But to our surprise, M&A activity worldwide has remained fairly stable.
Momentum Stock Market Game Plan
by David Bartosiak
Momentum Stock Strategist David Bartosiak gives Terry Ruffolo the stock market game plan for today
MedTech Industry Stock Outlook - July/Aug 2015
by Zacks Equity Research
Recently released government data showed that about 16.4 million uninsured people have gained health insurance coverage since the enactment of the Affordable Care Act five years back.
MedTech Industry Stock Outlook - July/Aug 2015
by Zacks Equity Research
Recently released government data showed that about 16.4 million uninsured people have gained health insurance coverage since the enactment of the Affordable Care Act five years back.
3 Best Stocks in the Market Today
by David Bartosiak
Stryker and 2 other hard hitting stock buys
MedTech M&As Continue Regardless of Tax Scenarios
by Zacks Equity Research
MedTech stalwarts are not expected to shy away from hostile acquisition bids this year.